Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Pancreatic Adenocarcinoma, Version 1.2019.

Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210. doi: 10.6004/jnccn.2019.0014.

PMID:
30865919
2.

Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer.

Ko AH.

Hepatobiliary Surg Nutr. 2018 Oct;7(5):406-408. doi: 10.21037/hbsn.2018.06.02. No abstract available.

3.

Understanding Pancreatic Diseases Using Animated Pancreas Patient: Informing Patients for Better Health Outcomes With Visual Formats of Learning.

Munigala S, Gardner TB, O╩╝Reilly EM, Castillo CF, Ko AH, Pleskow D, Mills JB, Vollmer CM Jr, Searle NA, Alsante M, Holt JM, Gelrud A.

Pancreas. 2018 Nov/Dec;47(10):1256-1261. doi: 10.1097/MPA.0000000000001178.

PMID:
30286013
4.

Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.

Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH.

Fam Cancer. 2018 Sep 28. doi: 10.1007/s10689-018-0106-2. [Epub ahead of print]

PMID:
30267352
5.

Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?

Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE.

Am J Surg Pathol. 2019 Mar;43(3):334-340. doi: 10.1097/PAS.0000000000001152.

PMID:
30211728
6.

Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.

Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA.

AJR Am J Roentgenol. 2018 Nov;211(5):1010-1019. doi: 10.2214/AJR.18.19602. Epub 2018 Jul 31.

PMID:
30063366
7.

Shifting the treatment model for resectable pancreatic cancer.

Ko AH.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):375-376. doi: 10.1016/S2468-1253(18)30094-3. Epub 2018 Apr 4. No abstract available.

PMID:
29625842
8.

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.

Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH.

JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013. Epub 2018 May 10.

9.

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran RB, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H.

J Clin Oncol. 2018 Apr 1;36(10):1020-1044. doi: 10.1200/JCO.2017.77.0446. Epub 2018 Jan 30.

PMID:
29380678
10.

Clinical Management: Metastatic Disease.

Ko AH.

Cancer J. 2017 Nov/Dec;23(6):355-361. doi: 10.1097/PPO.0000000000000294. Review.

PMID:
29189332
11.

A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.

Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS 4th, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC.

Oncologist. 2017 Dec;22(12):1427-e129. doi: 10.1634/theoncologist.2017-0066. Epub 2017 Sep 21.

12.

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S.

J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061. doi: 10.6004/jnccn.2017.0131.

PMID:
28784865
13.

Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.

Cinar P, Ko AH.

Chin Clin Oncol. 2017 Jun;6(3):29. doi: 10.21037/cco.2017.06.13. Review.

15.

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.

Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J.

Oncologist. 2017 Sep;22(9):1024-e89. doi: 10.1634/theoncologist.2017-0175. Epub 2017 Jun 7.

16.

Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.

Fidelman N, Kerlan RK Jr, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP.

J Gastrointest Oncol. 2016 Dec;7(6):860-874. doi: 10.21037/jgo.2016.08.04.

17.

Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity.

Woodard GA, Crockard JC, Clary-Macy C, Zoon-Besselink CT, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM.

J Surg Oncol. 2016 Dec;114(7):838-847. doi: 10.1002/jso.24409. Epub 2016 Aug 28.

PMID:
27569043
18.

Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?

Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH.

J Surg Oncol. 2016 Oct;114(5):587-596. doi: 10.1002/jso.24375. Epub 2016 Jul 21.

PMID:
27444658
19.

Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.

Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK.

Pancreas. 2016 Nov;45(10):1394-1400.

PMID:
27171514
20.

Striving to Move Beyond Chemotherapy in Advanced Pancreatic Cancer.

Ko AH.

J Oncol Pract. 2016 Sep;12(9):808-10. doi: 10.1200/JOP.2016.015933. No abstract available.

PMID:
27621334
21.

New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints.

Wang VE, Grandis JR, Ko AH.

Clin Cancer Res. 2016 Sep 1;22(17):4283-90. doi: 10.1158/1078-0432.CCR-16-0292. Epub 2016 Jul 1. Review.

22.

Raising the bar for the adjuvant treatment of pancreatic cancer.

Ko AH.

Lancet. 2016 Jul 16;388(10041):214-5. doi: 10.1016/S0140-6736(16)30680-8. Epub 2016 Jun 2. No abstract available.

PMID:
27265348
23.

Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB 3rd, Urba S, Yee NS.

J Clin Oncol. 2016 Aug 1;34(22):2654-68. doi: 10.1200/JCO.2016.67.5561. Epub 2016 May 31.

PMID:
27247216
24.

Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.

Ko AH.

Int J Nanomedicine. 2016 Mar 31;11:1225-35. doi: 10.2147/IJN.S88084. eCollection 2016. Review.

25.

A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers.

Coveler AL, Ko AH, Catenacci DV, Von Hoff D, Becerra C, Whiting NC, Yang J, Wolpin B.

Invest New Drugs. 2016 Jun;34(3):319-28. doi: 10.1007/s10637-016-0343-x. Epub 2016 Mar 18.

PMID:
26994014
26.

A Patient with HIV-Associated Metastatic Anal Squamous Cell Carcinoma Receiving Multimodality Therapy with Curative Intent: Case Report and Review of the Literature.

Kim SS, Kim GE, Ko AH.

J Gastrointest Cancer. 2017 Mar;48(1):94-99. doi: 10.1007/s12029-016-9814-8. Review. No abstract available.

PMID:
26961789
27.

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN.

Breast Cancer Res Treat. 2016 Feb;155(3):521-30. doi: 10.1007/s10549-016-3701-7. Epub 2016 Feb 13.

PMID:
26875185
28.

MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer.

Carnevale J, Ko AH.

Future Oncol. 2016 Feb;12(4):453-64. doi: 10.2217/fon.15.333. Epub 2015 Dec 21. Review.

PMID:
26685802
29.

Pancreatic Cancer and the Possibility of Long-term Survival: A Glimmer of Hope?

Ko AH.

JAMA Oncol. 2016 Mar;2(3):380-1. doi: 10.1001/jamaoncol.2015.4869. No abstract available.

PMID:
26658827
30.

A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.

Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL.

Pancreas. 2016 Mar;45(3):370-5. doi: 10.1097/MPA.0000000000000458.

31.

A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.

Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM.

Clin Cancer Res. 2016 Jan 1;22(1):61-8. doi: 10.1158/1078-0432.CCR-15-0979. Epub 2015 Aug 6.

32.

Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma.

Pollom EL, Koong AC, Ko AH.

Hematol Oncol Clin North Am. 2015 Aug;29(4):741-59. doi: 10.1016/j.hoc.2015.04.005. Epub 2015 May 30. Review.

PMID:
26226908
33.

Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.

Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA.

Cancer Discov. 2015 Oct;5(10):1040-8. doi: 10.1158/2159-8290.CD-15-0274. Epub 2015 Jun 24.

34.

Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value.

Ahn DH, Ko AH, Meropol NJ, Bekaii-Saab TS.

Am Soc Clin Oncol Educ Book. 2015:e222-7. doi: 10.14694/EdBook_AM.2015.35.e222. Review.

35.

Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities.

Ko AH.

J Clin Oncol. 2015 Jun 1;33(16):1779-86. doi: 10.1200/JCO.2014.59.7625. Epub 2015 Apr 27. Review.

PMID:
25918299
36.

Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study.

Walker EJ, Ko AH, Holly EA, Bracci PM.

Cancer. 2015 Apr 15;121(8):1287-94. doi: 10.1002/cncr.29256. Epub 2015 Feb 3.

37.

A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer.

Walker EJ, Simko JP, Nakakura EK, Ko AH.

J Gastrointest Oncol. 2014 Dec;5(6):E88-95. doi: 10.3978/j.issn.2078-6891.2014.051.

38.

Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study.

Walker EJ, Ko AH, Holly EA, Bracci PM.

Int J Cancer. 2015 Mar 15;136(6):E646-53. doi: 10.1002/ijc.29120. Epub 2014 Aug 14.

39.

Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab.

Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T.

Am J Clin Oncol. 2016 Dec;39(6):614-618.

40.
41.

Expanding options for pancreatic cancer... so where do we go from here?

Ko AH.

Oncology (Williston Park). 2014 Jan;28(1):5. No abstract available.

42.

Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab.

Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T.

Cancer. 2014 Jun 15;120(12):1780-6. doi: 10.1002/cncr.28648. Epub 2014 Mar 13. Erratum in: Cancer. 2015 Apr 1;121(7):1154.

43.

Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab.

Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH.

Pancreas. 2014 Apr;43(3):343-9. doi: 10.1097/MPA.0000000000000095.

44.

Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?

Walker EJ, Ko AH.

World J Gastroenterol. 2014 Mar 7;20(9):2224-36. doi: 10.3748/wjg.v20.i9.2224. Review.

45.

Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma.

Cinar P, Ko AH.

J Natl Compr Canc Netw. 2014 Feb;12(2):167-72.

PMID:
24586078
46.

90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.

Fidelman N, Kerlan RK Jr, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP.

J Gastrointest Cancer. 2014 Jun;45(2):168-80. doi: 10.1007/s12029-013-9566-7.

PMID:
24448917
47.

Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.

Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM.

Mol Cancer Ther. 2013 Oct;12(10):2213-25. doi: 10.1158/1535-7163.MCT-13-0104. Epub 2013 Aug 5.

48.

Achieving the best of both worlds.

Ko AH, Cella D.

J Clin Oncol. 2013 Jan 1;31(1):3-4. doi: 10.1200/JCO.2012.46.4891. Epub 2012 Dec 3. No abstract available.

PMID:
23213099
49.

A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.

Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA.

Cancer Chemother Pharmacol. 2012 Dec;70(6):875-81. doi: 10.1007/s00280-012-1979-7. Epub 2012 Sep 28.

PMID:
23053263
50.

Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers.

Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P.

Phys Biol. 2012 Feb;9(1):016003. doi: 10.1088/1478-3975/9/1/016003. Epub 2012 Feb 3.

Supplemental Content

Loading ...
Support Center